Unicycive Therapeutics UNCY 深 沪
等待开盘 04-02 09:30:00 美东时间
7.12
+0.540
+8.21%
华盛通- 最 高7.44
- 今 开6.63
- 成交量 116.62万股
- 最 低 6.61
- 昨 收 6.58
- 总市值 1.80亿
- 52周最高 11.00
- 市盈率 静 --
- 换手率 4.62%
- 52周最低 3.71
- 委 比 -82.05%
- 总股本 2523.78万
- 历史最高 87.30
- 量 比 2.35
- 振 幅 12.61%
- 历史最低 2.02
- 每 手 1
- 风险率 1.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Unicycive Therapeutics Q4 EPS $(0.82) Misses $0.03 Estimate
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.82) per share which missed the analyst consensus estimate of $0.03 by 2511.76 percent. This is a 68.46 percent increase over losses of $(2.60) per
03-30 19:53
Unicycive FY25 net loss narrows 28% to USD 27 million
Unicycive FY25 net loss narrows 28% to USD 27 million Unicycive posted a net loss of USD 27 million for fiscal 2025, narrowing 28%. Operating loss improved to USD 30 million as total operating expenses fell 8% to USD 30 million. Research and development costs dropped 54% to USD 9.1 million, while ge
03-30 18:33
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
Unicycive Therapeutics reports FDA review of OCA's NDA resubmission with a PDUFA date of June 29, 2026, and ongoing commercial readiness for a potential Q3 2026 launch. Financially, as of March 30, 2026, the company holds $54.9 million in cash and marketable securities, expecting runway into 2027. CEO Shalabh Gupta highlights the pivotal year with hopes for addressing uncontrolled hyperphosphatemia in dialysis patients.
03-30 11:05
Unicycive Therapeutics Faces Shareholder Lawsuit Over Alleged False Statements
Unicycive Therapeutics Faces Shareholder Lawsuit Over Alleged False Statements Grabar Law Office is investigating claims on behalf of shareholders of Unicycive Therapeutics Inc., alleging that certain officers and directors breached their fiduciary duties. The investigation centers on accusations th
02-17 22:16
Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and Launch Plans for OLC
Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and Launch Plans for OLC Unicycive Therapeutics Inc. has released a corporate presentation highlighting its progress in developing novel treatments for kidney disease. The company’s lead asset, oxylanthanum carbonate (OLC), is under revie
02-07 04:53
Unicycive Therapeutics Showcases Pipeline Advancements in Kidney Disease Treatments
Unicycive Therapeutics Showcases Pipeline Advancements in Kidney Disease Treatments Unicycive Therapeutics Inc. has released a corporate presentation detailing its progress in developing novel treatments for kidney diseases. The company’s lead asset, oxylanthanum carbonate (OLC), is being advanced f
01-31 04:47
BUZZ-U.S. STOCKS ON THE MOVE-Lockheed Martin, ManpowerGroup, Parker-Hannifin,
BUZZ-U.S. STOCKS ON THE MOVE-Lockheed Martin, ManpowerGroup, Parker-Hannifin, Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street looked set for a choppy open on Thursday as
01-29 23:48
BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, Summit, Lockheed Martin
BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, Summit, Lockheed Martin Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street looked set for a choppy open on Thursday as investors wad
01-29 22:18
BUZZ-Unicycive rises as FDA accepts resubmitted filing for kidney drug
BUZZ-Unicycive rises as FDA accepts resubmitted filing for kidney drug ** Shares of drug developer Unicycive Therapeutics UNCY.O rise 9.5% to $7.69 premarket ** Co says FDA accepted for review its resubmitted application for oxylanthanum carbonate, a pill for high phosphate levels in dialysis patien
01-29 20:15
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
Unicycive Therapeutics announced on January 29, 2026, that the FDA has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), an investigational oral phosphate binder for treating hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. The FDA assigned a PDUFA target date of June 27, 2026, to review the resubmission. The company ended 2025 with $41.3 million in cash, supporting its commercial...
01-29 12:05
